REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors

2012108 citationsJournal Article

Authors

Good health and well-being

Published in: Investigational New Drugs

Volume 31, Issue 3, pp. 696-706

Field-Weighted Citation Impact: 5.58